FDA Hears Concerns About The Unregulated CBD Market

  • Forbes | by: Holly Lawrence |
  • 06/04/2019 12:00 AM
A Call for Regulatory Oversight

The FDA hearing’s first speaker, Peter Pitts, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner, set the theme. “The absence to date, of advanced regulatory thinking relative to CBD has resulted in a maelstrom of false claims and shoddy quality standards,” Pitts said.

He called out “aggressive and misleading marketing campaigns” for CBD products, and urged, “It’s time for the proponents of CBD, including many highly vocal patients, physicians, pharmacists, manufacturers and distributors, to become part of the solution.

“Quality must always trump corporate convenience,” Pitts said, expressing the need for production quality oversight.

He also described a lack of a dosing schedule for CBD products. “When people are told to use CBD by physicians, pharmacists, friends or internet experts, they are not given any peer-reviewed guidelines on how they should take it or in what amounts — something that should never happen,” Pitts said.

 
Sign Up for Our Email Newsletter

RECENT NEWS

FDA is smashing the status quo for regulatory science

FDA is smashing the status quo for regulatory science

The most potent way the FDA can enable innovation is by being a partner in advancing new approaches to both drug developm...  Read more

True Cost of Socialized Medicine & the Right Way to Hold Down the Cost of Healthcare

True Cost of Socialized Medicine & the Right Way to Hold Down the Cost of Healthcare

...  Read more

Common Sense Healthcare Policy for Common Sense Americans (and Presidential Candidates)

Common Sense Healthcare Policy for Common Sense Americans (and Presidential Candidates)

Common Sense Healthcare Policy for Common Sense Americans is essential reading for anyone interested in practical solutio...  Read more

DRUGWONKS BLOG